| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and various inflammatory signaling pathways. Cimiside B exerts anti-inflammatory effects by upregulating PPAR-gamma and affecting various signaling pathways involved in inflammation. The compound modulates inflammatory responses through interactions with key regulatory proteins and transcription factors. Its glycoside alkaloid structure enables specific molecular interactions with targets involved in the inflammatory cascade. Cimiside B, along with related compounds such as cimiside E and 23-O-acetylshengmanol-3-xyloside, has been shown to share this anti-inflammatory mechanism.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Cimiside B exhibits notable anti-inflammatory activity. The compound modulates inflammatory signaling pathways in various cell types, reducing the production of pro-inflammatory cytokines and mediators. Its activity has been characterized in cell-based assays measuring inflammatory marker expression and signaling pathway activation. The compound's ability to upregulate PPAR-gamma contributes to its anti-inflammatory effects through the modulation of gene transcription. The glycoside alkaloid structure is essential for its biological activity and molecular interactions.
|
| ln Vivo |
In vivo studies of Cimiside B have been conducted in animal models of inflammation. The compound has been investigated for its ability to modulate inflammatory responses and regulate immune-related functions in vivo. Its anti-inflammatory properties make it a subject of interest for research focused on inflammation-associated mechanisms, cellular response modulation, and bioactive natural product evaluation. The compound's well-defined structure and bioactivity make it a useful tool for experimental research applications in inflammation and immunology.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Cimiside B typically measure its interaction with PPAR-gamma and other inflammatory targets. PPAR-gamma binding assays use purified recombinant PPAR-gamma ligand-binding domain and a fluorescent or radiolabeled ligand. The compound is incubated with the receptor in binding buffer, and displacement of the labeled ligand is measured. Alternatively, reporter gene assays are used where cells are transfected with PPAR-gamma response element-driven luciferase constructs and treated with Cimiside B. Luciferase activity is measured as a readout of PPAR-gamma activation. Other inflammatory targets such as NF-kappaB and COX-2 can be assessed using similar approaches.
|
| Cell Assay |
In vitro cell-based assays for Cimiside B use immune cells (macrophages, monocytes) or other cell types relevant to inflammation. Cells are cultured in appropriate media and treated with varying concentrations of the compound (typically 1-100 microM) for 12-24 hours, with or without inflammatory stimuli (e.g., LPS, TNF-alpha). Inflammatory markers measured include pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) by ELISA, nitric oxide production by Griess assay, and COX-2 and iNOS expression by Western blotting or qPCR. NF-kappaB activation is assessed by Western blotting for phosphorylated IkappaB or by nuclear translocation assays.
|
| Animal Protocol |
In vivo animal studies for Cimiside B are typically conducted in rodent models of inflammation. Common models include carrageenan-induced paw edema, zymosan-induced peritonitis, or LPS-induced systemic inflammation. Animals are administered the compound orally or intraperitoneally at doses of 10-100 mg/kg, either prophylactically or therapeutically. Inflammatory parameters measured include paw swelling, inflammatory cell infiltration, cytokine levels in plasma or tissue homogenates, and histological evaluation of tissue inflammation. The compound's effects on immune cell populations and inflammatory mediators are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cimiside B are characteristic of glycoside natural products. With a molecular weight of 752.93 and a glycoside structure, the compound is likely to have moderate water solubility but limited oral bioavailability due to its large molecular size and potential gastrointestinal metabolism. The compound is intended for research use only and is not formulated for clinical administration. Standard pharmacokinetic parameters (Cmax, Tmax, AUC, half-life) can be determined in preclinical species following appropriate routes of administration. Storage at -20degC is recommended to maintain stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cimiside B are limited to preclinical research studies. As a naturally occurring glycoside alkaloid, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicity profiles are not extensively documented. The compound is intended for research purposes only and not for human therapeutic use. Standard safety precautions for handling chemical compounds apply. Acute, subchronic, and chronic toxicity studies have not been systematically reported for this compound.
|
| Additional Infomation |
It was isolated from the rhizome of Cimicifuga dahurica; its structure is described in the first source.
Cimiside B is a research-grade naturally occurring glycoside alkaloid with anti-inflammatory activity. It is isolated from plant sources and is used as a research tool for studying inflammation mechanisms and immune regulation. The compound's molecular formula is C40H64O13 with a molecular weight of 752.93. Cimiside B is classified as a glycoside alkaloid and is structurally related to cimiside E and 23-O-acetylshengmanol-3-xyloside. It is supplied as a research compound with purity ≥95%. Not approved for clinical use. |
| Molecular Formula |
C40H64O13
|
|---|---|
| Molecular Weight |
752.92800
|
| Exact Mass |
752.434
|
| CAS # |
152685-91-1
|
| PubChem CID |
91895424
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.621
|
| LogP |
5.88
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
53
|
| Complexity |
1460
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@@H]1C[C@@H]2[C@H](O[C@]3([C@H]1[C@]4(CC[C@@]56C[C@@]57CC[C@@H](C([C@@H]7CC[C@H]6[C@@]4([C@H]3O)C)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O)C)O2)C(C)(C)O
|
| InChi Key |
FQXVWSGUAKXSLO-CKLOPMIDSA-N
|
| InChi Code |
InChI=1S/C40H64O13/c1-18-14-21-30(35(4,5)47)53-40(52-21)29(18)36(6)12-13-39-17-38(39)11-10-24(34(2,3)22(38)8-9-23(39)37(36,7)33(40)46)50-32-27(45)28(20(42)16-49-32)51-31-26(44)25(43)19(41)15-48-31/h18-33,41-47H,8-17H2,1-7H3/t18-,19-,20-,21-,22+,23+,24+,25+,26-,27-,28+,29-,30+,31+,32+,33-,36-,37-,38-,39+,40+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-[(2S,3R,4S,5R)-3,5-dihydroxy-2-[[(1S,2R,3S,4R,7R,9S,12R,14S,17R,18R,19R,21R,22S)-2-hydroxy-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.01,18.03,17.04,14.07,12.012,14]tetracosan-9-yl]oxy]oxan-4-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3281 mL | 6.6407 mL | 13.2814 mL | |
| 5 mM | 0.2656 mL | 1.3281 mL | 2.6563 mL | |
| 10 mM | 0.1328 mL | 0.6641 mL | 1.3281 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
